In Brief: REMS Removal for Clozapine

The FDA has announced that prescribers, pharmacies, and patients are no longer required to participate in a Risk Evaluation and Mitigation Strategy (REMS) program for the second-generation antipsychotic drug clozapine (Clozaril, and others).

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2025-06-09
DOI
https://doi.org/10.58347/tml.2025.1730e
Primary Topic
Extraction and Separation Processes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Brief: REMS Removal for Clozapine

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Extraction and Separation Processes
article

In Brief: REMS Removal for Clozapine

article en

Abstract

The FDA has announced that prescribers, pharmacies, and patients are no longer required to participate in a Risk Evaluation and Mitigation Strategy (REMS) program for the second-generation antipsychotic drug clozapine (Clozaril, and others).

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 67(1730)
Zero hunger
Openalex Percentile: Top 88%
Extraction and Separation Processes
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: REMS Removal for Clozapine · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2025) | TGRS Research Map | TGRS